Vion Announces Positive Data From Phase II Myelodysplastic Syndromes Trial
Posted on: Monday, 16 June 2008, 12:00 CDT
Vion Pharmaceuticals has reported positive data from a previously conducted Phase II trial of its lead anticancer agent Cloretazine in elderly patients with acute myelogenous leukemia and high-risk myelodysplastic syndromes.
The company presented the data in a subset of 26 patients with high-risk myelodysplastic syndromes (MDS) by French-American-British Group criteria. The median age of the patients in the subset was 71 years (range of 59-82 years). Approximately 12 patients were diagnosed with refractory anemia with excess blasts (RAEB) and nine patients were diagnosed with RAEB-t. Five patients were diagnosed with either chronic myelomonocytic leukemias (CMML) or as unknown.
Approximately 15 patients had intermediate cytogenetics and 11 had unfavorable cytogenetics. Approximately 16 of the patients were classified as Intermediate-2 risk by the International Prognostic Scoring System (1.5-2.0), and 10 were classified as high risk (greater than or equal to 2.5).
Eight of the 26 patients had received prior treatment for their disease. Prior agents used included arsenic trioxide, thalidomide, Ara-C, imatinib mesylate, interferon, amifostine, melphalan, hydroxyurea and 5-azacitiadine.
The overall complete response rate was 38% (7 CR and 3 CRp). Three of 10 responders received prior treatment; eight of the 10 responders received consolidation. The median (range) of overall survival for the entire patient group was 3.4 months (0.6-28.6) and the median (range) of overall survival for responders was 3.9 months (2.5-28.6).
Ghulam Mufti, department head and professor of hematological medicine at the University of London King's College Hospital, said: "The activity demonstrated in this study is encouraging, particularly the complete responses observed in those patients that had received prior treatment for MDS."
Source: Datamonitor
Related Articles
- Acute Heart Attack Patients Receiving High Ionizing Radiation Dose
- Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
- Only 44.4 Percent of Parkinson's Disease Patients Receive Drug Treatment Within One Year of Being Diagnosed
- New Data Show Preemptive Treatment May Significantly Reduce Skin Toxicities in Patients Receiving Vectibix(R) (Panitumumab)
- Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients With Higher-Risk Myelodysplastic Syndromes (MDS)
- European Commission Grants Orphan Medicinal Product Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for the Prevention of Pulmonary Fungal Infections in Patients Deemed At Risk
- Spine Surgeons Dr. Adelt and Dr. Bertagnoli Present Follow Up Data On Patients Receiving the Coflex(TM) Interspinous Implant
- Sepsis Drug Fails to Help Patients at Low Risk of Death
- Use of Sedatives and Neuromuscular Blockers in a Cohort of Patients Receiving Mechanical Ventilation*
- Cost-Effectiveness in Italy of Preventive Treatment With Ramipril in Patients at High Risk of Cardiovascular Events
 |
 |
User Comments (0)
RSS Feeds